Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Malignant Neoplasms”

5,754 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 5,754 results

Testing effectiveness (Phase 2)UnknownNCT01300156
What this trial is testing

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

Who this might be right for
Hodgkin's Lymphoma
National Cancer Center, Korea 37
Testing effectiveness (Phase 2)Ended earlyNCT02689219
What this trial is testing

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Who this might be right for
Germ Cell TumorsTestis CancerTesticular Cancer+2 more
Nabil Adra 18
Testing effectiveness (Phase 2)Study completedNCT04835519
What this trial is testing

Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaRelapse LeukemiaRefractory Acute Myeloid Leukemia
Beijing Boren Hospital 5
Testing effectiveness (Phase 2)Study completedNCT03126019
What this trial is testing

INCB050465 in Relapsed or Refractory Follicular Lymphoma

Who this might be right for
Lymphoma
Incyte Corporation 126
Testing effectiveness (Phase 2)Study completedNCT00002907
What this trial is testing

Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Barbara Ann Karmanos Cancer Institute
Early research (Phase 1)UnknownNCT03015922
What this trial is testing

Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Leeds 4
Early research (Phase 1)Study completedNCT01238237
What this trial is testing

Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA

Who this might be right for
Glioblastoma Multiforme (GBM)ANAPLASTIC ASTROCYTOMA (AOA)GBM+1 more
Northwell Health 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT04842877
What this trial is testing

Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
The Lymphoma Academic Research Organisation 141
Not applicableStudy completedNCT00521430
What this trial is testing

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+3 more
Asan Medical Center 30
Early research (Phase 1)Looking for participantsNCT06547528
What this trial is testing

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Who this might be right for
Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Ono Pharmaceutical Co., Ltd. 108
Testing effectiveness (Phase 2)Study completedNCT01532700
What this trial is testing

An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)
University Health Network, Toronto 28
Large-scale testing (Phase 3)Looking for participantsNCT06713837
What this trial is testing

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Who this might be right for
Acute Myeloid LeukemiaRelapse/Recurrence
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 339
Testing effectiveness (Phase 2)Study completedNCT00684619
What this trial is testing

506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)

Who this might be right for
T-ALL, T-NHL (Lymphoblastic)
Goethe University 120
Testing effectiveness (Phase 2)Study completedNCT03403777
What this trial is testing

Avelumab in Refractory Testicular Germ Cell Cancer.

Who this might be right for
Testicular NeoplasmsNeoplasms, Germ Cell and EmbryonalNeoplasms+4 more
National Cancer Institute, Slovakia 8
Testing effectiveness (Phase 2)Looking for participantsNCT05147467
What this trial is testing

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Ascentage Pharma Group Inc. 75
Testing effectiveness (Phase 2)Study completedNCT00895934
What this trial is testing

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

Who this might be right for
Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)+11 more
National Cancer Institute (NCI) 52
Early research (Phase 1)Looking for participantsNCT05292664
What this trial is testing

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Who this might be right for
Myelodysplastic Syndromes, de NovoMyelodysplastic Syndromes, SecondaryMyelodysplastic Syndromes, Previously Treated+8 more
Andrew E. Place, MD 30
Testing effectiveness (Phase 2)Study completedNCT03145064
What this trial is testing

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
BeiGene 41
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Not applicableStudy completedNCT02976493
What this trial is testing

Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 500
Load More Results